Breast Cancer – Current Treatment – Detailed, Expanded Analysis (EU5)
KEY BENEFITS AND USES
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand which drugs to position against or how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources, and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
QUESTIONS ANSWERED
- Where is my product positioned versus competitors’ products in the treatment journey?
- What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios, according to oncology experts?
- Where are the untapped business opportunities on which I can capitalize?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians.
GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. physicians
Table of contents
- Breast Cancer - Current Treatment - Detailed, Expanded Analysis (EU5)
- Current Treatment: Physicians Insights Breast Cancer EU5 June 2021
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.
Carolina do Pazo, M.Sc., is a senior analyst on the Oncology team at Clarivate. She has authored content on breast cancer, SCCHN, ovarian cancer, and prostate cancer. Previously, she was a research scientist at the Institut Pasteur de Montevideo, where she analyzed the aging process of yeast cells, and she was part of a project between Indiana University and the Universidad ORT that analyzed the production of nanohybrids for drug delivery system applications. As a Chevening Scholar, Ms. Do Pazo completed an M.Sc. in biotechnology, bioprocessing, and business management with distinction at the University of Warwick. She also earned her first-class M.Eng. in biotechnology from the Universidad ORT.